Lorigerlimab

Lorigerlimab (MGD019) is a bispecific antibody developed by MacroGenics. Its targets are PD-1 and CTLA-4 (the sponsor names PD-1 x CTLA-4). The sponsor states: A DART (Dual Affinity Re-Targeting) bispecific protein that simultaneously engages the PD-1 and CTLA-4 checkpoint pathways to enhance anti-tumour immune responses. ClinicalTrials.gov describes the intervention as: Bispecific DART protein binding PD-1 and CTLA-4. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in ovarian cancer, vulvar cancer, cervical cancer and endometrial cancer. The largest, NCT06730347, plans to enrol 80 participants with primary completion expected 2027-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.